At the 60th Annual Meeting of the American Society of Hematology (ASH), Laura Michaelis from Medical College of Wisconsin, Milwaukee, US, talks about the use of cytotoxic induction therapy in acute myeloid leukemia (AML). She argued that it is too early to get rid of cytotoxic therapy in AML as it does something that all the targeted agents don't do, as it treats what is common among patients with AML.
Laura Michaelis | ASH 2018 | Moving beyond 7 + 3 in acute myeloid leukemia
Was this article informative? Thank you for your feedback!0% of people found this article informative